Table 3.
BI | Age | DASH | Grip affected side | Grip unaffected side | Lymphedema stage | Lymphedema duration | Edema | VAS pain | VAS tension | VAS heaviness | EORTC QLQ-30 FS | EORTC QLQ-30 SS | EORTC QLQ-30 GHS | EORTC QLQ BRE-23 FS | EORTC QLQ BRE-23 SS | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BI | r | 1 | 0.002 | 0.535** | −0.440** | −0.284* | 0.228 | −0.277* | 0.271 | 0.360** | 0.180 | 0.238 | −0.622** | 0.592** | −0.266 | −0.200 | 0.231 |
p | 0.991 | 0.000 | 0.001 | 0.043 | 0.105 | 0.049 | 0.052 | 0.010 | 0.203 | 0.089 | 0.000 | 0.000 | 0.057 | 0.209 | 0.174 | ||
Age(years) | r | 0.002 | 1 | −0.027 | 0.057 | −0.064 | 0.348* | −0.081 | 0.124 | −0.319* | −0.252 | −0.018 | −0.053 | −0.003 | −0.052 | 0.399** | 0.211 |
p | 0.991 | 0.851 | 0.693 | 0.654 | 0.011 | 0.572 | 0.380 | 0.023 | 0.071 | 0.896 | 0.717 | 0.985 | 0.716 | 0.010 | 0.217 | ||
DASH | r | 0.535** | −0.027 | 1 | −0.508** | −0.321* | 0.371** | −0.161 | 0.291* | 0.356* | 0.321* | 0.442** | −0.627** | 0.531** | −0.435** | −0.275 | 0.119 |
p | 0.000 | 0.851 | 0.000 | 0.022 | 0.007 | 0.265 | 0.038 | 0.011 | 0.022 | 0.001 | 0.000 | 0.000 | 0.001 | 0.086 | 0.495 | ||
Grip affected side(kgf) | r | −0.440** | 0.057 | −0.508** | 1 | 0.632** | −0.051 | 0.067 | −0.057 | −0.487** | −0.195 | −0.109 | 0.301* | −0.313* | 0.077 | 0.188 | −0.126 |
p | 0.001 | 0.693 | 0.000 | 0.000 | 0.724 | 0.646 | 0.693 | 0.000 | 0.170 | 0.446 | 0.037 | 0.025 | 0.589 | 0.244 | 0.471 | ||
Grip unaffected side(kgf) | r | −0.284* | −0.064 | −0.321* | 0.632** | 1 | −0.001 | 0.050 | −0.014 | −0.246 | 0.030 | 0.012 | 0.368* | −0.259 | −0.087 | 0.351* | −0.278 |
p | 0.043 | 0.654 | 0.022 | 0.000 | 0.992 | 0.732 | 0.923 | 0.085 | 0.833 | 0.932 | 0.010 | 0.066 | 0.546 | 0.026 | 0.106 | ||
Lymphedema stage | r | 0.228 | 0.348* | 0.371** | −0.051 | −0.001 | 1 | −0.214 | 0.632** | 0.031 | 0.285* | 0.375** | −0.363* | 0.206 | −0.254 | 0.092 | 0.180 |
p | 0.105 | 0.011 | 0.007 | 0.724 | 0.992 | 0.132 | 0.000 | 0.829 | 0.041 | 0.006 | 0.010 | 0.143 | 0.069 | 0.569 | 0.294 | ||
Lymphedema duration | r | −0.277* | −0.081 | −0.161 | 0.067 | 0.050 | −0.214 | 1 | 0.031 | −0.016 | −0.053 | −0.054 | 0.182 | −0.214 | 0.253 | −0.033 | 0.051 |
p | 0.049 | 0.572 | 0.265 | 0.646 | 0.732 | 0.132 | 0.831 | 0.913 | 0.710 | 0.708 | 0.217 | 0.132 | 0.073 | 0.838 | 0.772 | ||
Edema | r | 0.271 | 0.124 | 0.291* | −0.057 | −0.014 | 0.632** | 0.031 | 1 | 0.060 | 0.306* | 0.368** | −0.149 | 0.033 | −0.126 | 0.096 | 0.007 |
p | 0.052 | 0.380 | 0.038 | 0.693 | 0.923 | 0.000 | 0.831 | 0.678 | 0.027 | 0.007 | 0.306 | 0.814 | 0.374 | 0.550 | 0.969 | ||
VAS pain | r | 0.360** | −0.319* | 0.356* | −0.487** | −0.246 | 0.031 | −0.016 | 0.060 | 1 | 0.496** | 0.366** | −0.125 | 0.315* | −0.148 | 0.002 | 0.040 |
p | 0.010 | 0.023 | 0.011 | 0.000 | 0.085 | 0.829 | 0.913 | 0.678 | 0.000 | 0.008 | 0.398 | 0.024 | 0.299 | 0.989 | 0.817 | ||
VAS tension | r | 0.180 | −0.252 | 0.321* | −0.195 | 0.030 | 0.285* | −0.053 | 0.306* | 0.496** | 1 | 0.644** | −0.308* | 0.260 | −0.190 | −0.023 | 0.126 |
p | 0.203 | 0.071 | 0.022 | 0.170 | 0.833 | 0.041 | 0.710 | 0.027 | 0.000 | 0.000 | 0.032 | 0.062 | 0.177 | 0.887 | 0.465 | ||
VAS heaviness | r | 0.238 | −0.018 | 0.442** | −0.109 | 0.012 | 0.375** | −0.054 | 0.368** | 0.366** | 0.644** | 1 | −0.343* | 0.350* | −0.374** | −0.038 | 0.230 |
p | 0.089 | 0.896 | 0.001 | 0.446 | 0.932 | 0.006 | 0.708 | 0.007 | 0.008 | 0.000 | 0.016 | 0.011 | 0.006 | 0.815 | 0.177 | ||
EORTC QLQ-30 FS | r | −0.622** | −0.053 | −0.627** | 0.301* | 0.368* | −0.363* | 0.182 | −0.149 | −0.125 | −0.308* | −0.343* | 1 | −0.769** | 0.140 | 0.558** | −0.336 |
p | 0.000 | 0.717 | 0.000 | 0.037 | 0.010 | 0.010 | 0.217 | 0.306 | 0.398 | 0.032 | 0.016 | 0.000 | 0.336 | 0.000 | 0.052 | ||
EORTC QLQ-30 SS | r | 0.592** | −0.003 | 0.531** | −0.313* | −0.259 | 0.206 | −0.214 | 0.033 | 0.315* | 0.260 | 0.350* | −0.769** | 1 | −0.285* | −0.449** | 0.387* |
p | 0.000 | 0.985 | 0.000 | 0.025 | 0.066 | 0.143 | 0.132 | 0.814 | 0.024 | 0.062 | 0.011 | 0.000 | 0.041 | 0.003 | 0.020 | ||
EORTC QLQ-30 GHS | r | −0.266 | −0.052 | −0.435** | 0.077 | −0.087 | −0.254 | 0.253 | −0.126 | −0.148 | −0.190 | −0.374** | 0.140 | −0.285* | 1 | 0.115 | −0.093 |
p | 0.057 | 0.716 | 0.001 | 0.589 | 0.546 | 0.069 | 0.073 | 0.374 | 0.299 | 0.177 | 0.006 | 0.336 | 0.041 | 0.474 | 0.589 | ||
EORTC QLQ BRE-23 FS | r | −0.200 | 0.399** | −0.275 | 0.188 | 0.351* | 0.092 | −0.033 | 0.096 | 0.002 | −0.023 | −0.038 | 0.558** | −0.449** | 0.115 | 1 | −0.314 |
p | 0.209 | 0.010 | 0.086 | 0.244 | 0.026 | 0.569 | 0.838 | 0.550 | 0.989 | 0.887 | 0.815 | 0.000 | 0.003 | 0.474 | 0.104 | ||
EORTC QLQ BRE-23 SS | r | 0.231 | 0.211 | 0.119 | −0.126 | −0.278 | 0.180 | 0.051 | 0.007 | 0.040 | 0.126 | 0.230 | −0.336 | 0.387* | −0.093 | −0.314 | 1 |
p | 0.174 | 0.217 | 0.495 | 0.471 | 0.106 | 0.294 | 0.772 | 0.969 | 0.817 | 0.465 | 0.177 | 0.052 | 0.020 | 0.589 | 0.104 |
BI: burden interview; VAS: visual analogue scale; DASH: disabilities of the arm, shoulder and hand; EORTC QLQ: European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire; FS: function score; SS: symptom score; GHS: general health score; BRE-23: Breast cancer module